Rosalba Miceli
University of Milan
Interquartile rangeCancerRadiologySurgeryOncologyRetrospective cohort studySurvival rateChemotherapySarcomaSoft tissue sarcomaPrimary tumorTransplantationNomogramProportional hazards modelRadiation therapyColorectal cancerBreast cancerMedicineCumulative incidenceGastroenterology
Publications 282
#1Cristina Gurizzan (University of Brescia)H-Index: 1
#2Luigi Lorini (University of Brescia)H-Index: 2
Last. Paolo Bossi (University of Brescia)H-Index: 37
view all 18 authors...
Background Oral Potentially Malignant Disorders (OPMD) have a non-negligible malignant transformation rate of up to 8%. Loss of heterozygosity (LOH) in critical chromosomal loci has proven to be the most effective marker in defining the risk of transformation and it is found in about 28% of OPMD and may therefore identify patients carrying higher risk. To date, clinical management of OPMD is limited to surgical excision and clinical surveillance, which however do not fully prevent oral cancer de...
#1S. Di CosimoH-Index: 15
#2Catherine DeprettoH-Index: 2
Last. Gianfranco ScaperrottaH-Index: 7
view all 11 authors...
#1Carolyn Nessim (Ottawa Hospital Research Institute)H-Index: 6
#1Carolyn Nessim (Ottawa Hospital Research Institute)H-Index: 5
Last. Sanjay P. Bagaria (Mayo Clinic)H-Index: 22
view all 27 authors...
BACKGROUND Local recurrence following resection of retroperitoneal liposarcoma (RLPS) is common. Well-differentiated (WD) and dedifferentiated (DD) RLPS are distinct entities with differing outcomes. A few reports suggest that WDLPS can recur as DDLPS and that DDLPS can recur as WDLPS. This study evaluates whether this change in differentiation from the primary tumor to the first local recurrence impacts long-term outcomes. METHODS Retrospective review from 22 sarcoma centers identified consecut...
#1Maria Di BartolomeoH-Index: 28
#2Alessandra RaimondiH-Index: 10
Last. Filippo Pietrantonio (University of Milan)H-Index: 30
view all 30 authors...
Background:No predictive markers for chemotherapy activity have been validated in gastric cancer (GC). The potential value of class III β-tubulin (TUBB3) as biomarker for prognosis and resistance t...
#1E. OrtolanH-Index: 1
#2Valentina AppiertoH-Index: 15
Last. S. Di CosimoH-Index: 15
view all 17 authors...
Background As neoadjuvant chemotherapy (NAC) is increasingly used in triple-negative breast cancer (TNBC), we investigated the value of circulating tumor DNA (ctDNA) for patient monitoring prior, during, and after NAC, and circulating tumor cells (CTCs) for disease characterization at clinical progression. Materials and methods Forty-two TNBC patients undergoing NAC were prospectively enrolled. Primary tumor mutations identified by targeted-gene sequencing were validated and tracked in 168 plasm...
#1A.M. Frezza (University of Milan)H-Index: 7
#2Andrea Napolitano (Università Campus Bio-Medico)H-Index: 21
Last. Alessandro GronchiH-Index: 88
view all 17 authors...
BACKGROUND This multicentric, retrospective study conducted within the Italian Rare Cancer Network describes clinical features and explores their possible prognostic relevance in patients with advanced epithelioid haemangioendothelioma (EHE) started on surveillance. PATIENTS AND METHODS We collected data on adult patients with molecularly confirmed, advanced EHE consecutively referred at five sarcoma reference centres between January 2010 and June 2018, with no evidence of progressive disease (P...
#1Dario Callegaro (U of T: University of Toronto)H-Index: 18
#2Chandrajit P. Raut (Brigham and Women's Hospital)H-Index: 62
Last. Carol J. Swallow (U of T: University of Toronto)H-Index: 28
view all 19 authors...
BACKGROUND This study aimed to investigate changes in treatment strategy and outcome for patients with primary retroperitoneal sarcoma (RPS) undergoing resection at referral centers during a recent period. METHODS The study enrolled consecutive adult patients with primary non-metastatic RPS who underwent resection with curative intent between 2002 and 2017 at 10 referral centers. The patients were grouped into three periods according to date of surgery: t1 (2002-2006), t2 (2007-2011), and t3 (20...
4 CitationsSource
Background: The RESORT trial showed no longer relapse free survival (RFS) with sorafenib following radical metastasectomy versus observation in metastatic renal cell carcinoma patients. We present the updated 42-month follow up data. Methods: The phase II RESORT trial randomized patients (1:1) to sorafenib or observation for 52 weeks within 12 weeks from surgery. RFS, the time from randomization to disease relapse or death, was the primary endpoint. Results: Sixty-nine patients were randomized b...
#1Maria DanieliH-Index: 1
#2Francesco BarrettaH-Index: 13
Last. Alessandro GronchiH-Index: 88
view all 12 authors...
PURPOSE The need for systematic reexcision in patients who underwent unplanned excision (UE) for extremity and superficial trunk soft tissue sarcoma (ESTSTS) has been questioned. We investigated the outcome of patients who underwent reexcision for ESTSTS compared with primarily resected at our institution and the prognostic impact of microscopic residual disease (MR) in the reexcision specimen. METHODS Primary ESTSTS patients surgically treated at our institution between 1997 and 2017 were divid...
1 CitationsSource
#1Filippo Pietrantonio (University of Milan)H-Index: 30
#2Gabriele InfanteH-Index: 6
Last. Rosalba MiceliH-Index: 62
view all 20 authors...
87Background: Anti-PD-(L)1-based therapy yielded unprecedented efficacy in patients with MSI-high mCRC. A relevant proportion of subjects may achieve long-term disease control when receiving ICIs, ...